Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
02096.HK
SIMCERE PHARMA (02096.HK): SIM0712 Cleared for Atopic Dermatitis Trial
Tags:
SIMCERE PHARMA
02096.HK
Clinical Trial
2026-11-16
SIMCERE PHARMA (02096.HK): Sublingual Stroke Drug Added to 2026 National Reimbursement List
Tags:
NewTimeSpace
SIMCERE PHARMA
02096.HK
2026-11-16
SIMCERE PHARMA (02096.HK): SIM0725 Cleared for Clinical Trial in Autoimmune Diseases
Tags:
NewTimeSpace
SIMCERE PHARMA
02096.HK
2026-11-10
SIMCERE PHARMA (02096.HK): SIM0709 trial cleared in Germany
Tags:
SIMCERE PHARMA
02096.HK
Clinical Trial
2026-11-09
SIMCERE PHARMA (02096.HK): zemprocitinib RA NDA accepted by NMPA
Tags:
SIMCERE PHARMA
02096.HK
New Drug Application
2026-11-06
SIMCERE PHARMA (02096.HK): Zemprocitinib dermatology rights secured
Tags:
SIMCERE PHARMA
02096.HK
Business Update
2026-11-02
SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China
Tags:
SIMCERE PHARMA
02096.HK
R&D Progress
2026-09-04
SIMCERE PHARMA(02096.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 828.72 million, YoY increase of 37.88%
Tags:
SIMCERE PHARMA
02096.HK
profit growth
2026-08-21
SIMCERE PHARMA (02096.HK): Zhu Da appointed Joint Company Secretary succeeding Wan Yushan, waiver granted from company secretary qualification requirements
Tags:
SIMCERE PHARMA
02096.HK
Board Change
2026-08-21
SIMCERE PHARMA (02096.HK): First-in-Class Innovative Drug Xibi Xin® (Edaravone and Dexborneol) Included in 2026 National Essential Medicines List
Tags:
SIMCERE PHARMA
02096.HK
Pharmaceutical Updates
2026-07-09
SIMCERE PHARMA(02096.HK): PD-1/VEGF Bispecific Antibody SIM0689 Approved for Clinical Trials by NMPA
Tags:
SIMCERE PHARMA
02096.HK
ClinicalTrialApproval
2026-06-12
SIMCERE PHARMA (02096.HK): SIM0613 (LRRC15 ADC) Receives NMPA Clinical Trial Approval
Tags:
SIMCERE PHARMA
02096.HK
ClinicalTrialApproval
2026-05-06
SIMCERE PHARMA(02096.HK) will spend HKD 22.21 million to repurchase 1.88 million shares on Jan 20, 2026
Tags:
SIMCERE PHARMA
02096.HK
2026-01-21
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App